Guided by science, we relentlessly build on our immunologic expertise and technologies in pursuit of transformative medicines to help patients worldwide facing serious infectious diseases. Our discoveries and innovations are the result of the passion and dedication of our team of world-class scientists.”

Filippo Riva, Managing Director of Humabs BioMed

Swiss Biotech Success Stories Award winner 2023
Humabs BioMed, a wholly owned subsidiary of Vir Biotechnology

As a wholly owned subsidiary of Vir Biotechnology (Nasdaq: VIR), Humabs BioMed and its immunologic expertise and cutting-edge technology is enabling the delivery of innovative solutions to address the world’s most serious infectious diseases.

The antibodies discovered and developed by Humabs have helped Vir transform the infectious disease landscape. From Ebola to COVID-19, their success in delivering novel commercialized medicines has given Vir the financial strength and experience needed to advance its robust pipeline.

Humabs is recognized for its pioneering role in the discovery, engineering, and early development of human monoclonal antibodies to fight infectious diseases. The world class scientific team at Humabs has published its scientific discoveries in dozens of prestigious peer-reviewed scientific journals such as Science, Nature and Cell.

Humabs was co-founded in 2004 by Dr. Antonio Lanzavecchia, a renowned immunologist and founding director of the Institute for Research in Biomedicine (IRB) in Bellinzona, and Dr. William J. Rutter, an industry veteran, academic and successful entrepreneur. It was acquired by Vir in 2017 and its antibody discoveries play an important role in collaborations with institutions such as the U.S. Biomedical Advanced Research and Development Authority.

2023 will be a pivotal year for Vir, with Phase II data readouts expected for three of the company’s advanced development programs in flu, hepatitis B and hepatitis D virus infection – all clinical trials evaluating investigational monoclonal antibodies that came out of the work at Humabs in Bellinzona.

Humabs BioMed, a pioneer in the discovery, engineering, and early development of human monoclonal antibodies to fight infectious diseases.

Swiss Biotech Success Stories Award winner 2023
Humabs BioMed, a wholly owned subsidiary of Vir Biotechnology